---
title: "Liquidia Corporation (LQDA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LQDA.US.md"
symbol: "LQDA.US"
name: "Liquidia Corporation"
industry: "Pharmaceuticals"
datetime: "2026-06-10T02:29:01.046Z"
locales:
  - [en](https://longbridge.com/en/quote/LQDA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LQDA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LQDA.US.md)
---

# Liquidia Corporation (LQDA.US)

## Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.liquidia.com](https://www.liquidia.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-09T04:30:17.000Z

**Overall: B (0.25)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 14 / 194 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1936.66% |  |
| Net Profit YoY | 116.33% |  |
| P/B Ratio | 52.34 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5682505526.10 |  |
| Revenue | 288065000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 28.18% | A |
| Profit Margin | 7.74% | B |
| Gross Margin | 91.08% | A |
| Revenue YoY | 1936.66% | A |
| Net Profit YoY | 116.33% | A |
| Total Assets YoY | 76.55% | A |
| Net Assets YoY | 118.41% | A |
| Cash Flow Margin | 215.12% | B |
| OCF YoY | 1936.66% | A |
| Turnover | 0.92 | A |
| Gearing Ratio | 72.96% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Liquidia Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1936.66%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "116.33%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "52.34",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5682505526.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "288065000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "28.18%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "7.74%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "91.08%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1936.66%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "116.33%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "76.55%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "118.41%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "215.12%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1936.66%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.92",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "72.96%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 255.20 | 57/194 | 247.29 | 243.12 | 226.97 |
| PB | 52.43 | 195/194 | 141.15 | 114.84 | 45.61 |
| PS (TTM) | 19.76 | 129/194 | 103.33 | 46.00 | 21.23 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-05T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Overweight | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 64.01 |
| Highest Target | 71.00 |
| Lowest Target | 59.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LQDA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LQDA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LQDA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LQDA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**